Scientific Background and Reference Sources
Aletaha, D., Nell, V. P., Stamm, T., Uffmann, M., Pflugbeil, S., Machold, K., & Smolen, J. S. (2005). Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther, 7(4), R796-806. doi:10.1186/ar1740
Anderson, J., Caplan, L., Yazdany, J., Robbins, M. L., Neogi, T., Michaud, K., Kazi, S. (2012). Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken), 64(5), 640-647. doi:10.1002/acr.21649
Bakker, M. F., Cavet, G., Jacobs, J. W., Bijlsma, J. W., Haney, D. J., Shen, Y., Welsing, P. M. (2012). Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis, 71(10), 1692-1697. doi:10.1136/annrheumdis-2011-200963
Brown, A. K., Quinn, M. A., Karim, Z., Conaghan, P. G., Peterfy, C. G., Hensor, E., Emery, P. (2006). Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum, 54(12), 3761-3773. doi:10.1002/art.22190
Centola, M., Cavet, G., Shen, Y., Ramanujan, S., Knowlton, N., Swan, K. A., Curtis, J. R. (2013). Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis. PLoS One, 8(4). doi:10.1371/journal.pone.0060635
Chambers, R. E., MacFarlane, D. G., Whicher, J. T., & Dieppe, P. A. (1983). Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Ann Rheum Dis, 42(6), 665-667.
Combe, B., Landewe, R., Lukas, C., Bolosiu, H. D., Breedveld, F., Dougados, M., Yazici, H. (2007). EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis, 66(1), 34-45. doi:10.1136/ard.2005.044354
Curtis, J. R., van der Helm-van Mil, A. H., Knevel, R., Huizinga, T. W., Haney, D. J., Shen, Y., Weinblatt, M. E. (2012). Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken), 64(12), 1794-1803. doi:10.1002/acr.21767
Firestein, G. (2017). Pathogenesis of rheumatoid arthritis - UpToDate. In P. L. Romain (Ed.), UpToDate. Waltham. MA. Retrieved from https://www.uptodate.com/contents/pathogenesis-ofrheumatoid-arthritis?source=search_result&search=ra&selectedTitle=6~150.
Fleischmann, R., Connolly, S. E., Maldonado, M. A., & Schiff, M. (2016). Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab. Arthritis Rheumatol, 68(9), 2083- 2089. doi:10.1002/art.39714
Goekoop-Ruiterman, Y. P., de Vries-Bouwstra, J. K., Allaart, C. F., van Zeben, D., Kerstens, P. J., Hazes, J. M., Dijkmans, B. A. (2005). Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum, 52(11), 3381-3390. doi:10.1002/art.21405
Grigor, C., Capell, H., Stirling, A., McMahon, A. D., Lock, P., Vallance, R., Porter, D. (2004). Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet, 364(9430), 263-269. doi:10.1016/s0140- 6736(04)16676-2
Hambardzumyan, K., Bolce, R., Saevarsdottir, S., Cruickshank, S. E., Sasso, E. H., Chernoff, D., van Vollenhoven, R. F. (2015). Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis, 74(6), 1102-1109. doi:10.1136/annrheumdis-2013-204986
Hammer, H. B., Odegard, S., Fagerhol, M. K., Landewe, R., van der Heijde, D., Uhlig, T., Kvien, T. K. (2007). Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis, 66(8), 1093-1097. doi:10.1136/ard.2006.064741
Hirata, S., Dirven, L., Shen, Y., Centola, M., Cavet, G., Lems, W. F., Allaart, C. F. (2013). A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology (Oxford), 52(7), 1202-1207. doi:10.1093/rheumatology/kes362
Keenan, R. T., Swearingen, C. J., & Yazici, Y. (2008). Erythrocyte sedimentation rate and Creactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients. Clin Exp Rheumatol, 26(5), 814-819.
Klarenbeek, N. B., Koevoets, R., van der Heijde, D. M., Gerards, A. H., Ten Wolde, S., Kerstens, P. J., Allaart, C. F. (2011). Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis, 70(10), 1815-1821. doi:10.1136/ard.2010.149260
Klimiuk, P. A., Sierakowski, S., Latosiewicz, R., Cylwik, J. P., Cylwik, B., Skowronski, J., & Chwiecko, J. (2002). Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis, 61(9), 804-809.
Li, W., Sasso, E. H., Emerling, D., Cavet, G., & Ford, K. (2013). Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use. Curr Med Res Opin, 29(1), 85-92. doi:10.1185/03007995.2012.753042
Lillegraven, S., Prince, F. H., Shadick, N. A., Bykerk, V. P., Lu, B., Frits, M. L., Solomon, D. H. (2012). Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis, 71(5), 681-686. doi:10.1136/ard.2011.154625
Mease, P. J. (2011). The potential roles for novel biomarkers in rheumatoid arthritis assessment. Clin Exp Rheumatol, 29(3), 567-574.
Pincus, T., Swearingen, C. J., Bergman, M., & Yazici, Y. (2008). RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol, 35(11), 2136-2147.
Pincus, T., Yazici, Y., Bergman, M., Maclean, R., & Harrington, T. (2007). A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative routine assessment of patient index data (RAPID) scores on a multidimensional health assessment questionnaire (MDHAQ). Best Pract Res Clin Rheumatol, 21(4), 789-804. doi:10.1016/j.berh.2007.02.009
Prevoo, M. L., van 't Hof, M. A., Kuper, H. H., van Leeuwen, M. A., van de Putte, L. B., & van Riel, P. L. (1995). Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum, 38(1), 44-48.
Rezaei, H., Saevarsdottir, S., Forslind, K., Albertsson, K., Wallin, H., Bratt, J., van Vollenhoven, R. F. (2012). In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Ann Rheum Dis, 71(2), 186- 191. doi:10.1136/annrheumdis-2011-200038
Rhodes, B., Merriman, M. E., Harrison, A., Nissen, M. J., Smith, M., Stamp, L., Vyse, T. J. (2010). A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation. PLoS Med, 7(9), e1000341. doi:10.1371/journal.pmed.1000341
Saleem, B., Brown, A. K., Keen, H., Nizam, S., Freeston, J., Karim, Z., Emery, P. (2009). Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: A clinical and imaging comparative study. Arthritis Rheum, 60(7), 1915-1922. doi:10.1002/art.24596
Singh, J. A., Furst, D. E., Bharat, A., Curtis, J. R., Kavanaugh, A. F., Kremer, J. M., Saag, K. G. (2012). 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken), 64(5), 625-639. doi:10.1002/acr.21641
Singh, J. A., Saag, K. G., Bridges, S. L., Jr., Akl, E. A., Bannuru, R. R., Sullivan, M. C., McAlindon, T. (2016). 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken), 68(1), 1-25. doi:10.1002/acr.22783
Smolen, J. S., Aletaha, D., Bijlsma, J. W., Breedveld, F. C., Boumpas, D., Burmester, G., van der Heijde, D. (2010). Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis, 69(4), 631-637. doi:10.1136/ard.2009.123919
Smolen, J. S., Breedveld, F. C., Schiff, M. H., Kalden, J. R., Emery, P., Eberl, G., Tugwell, P. (2003). A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford), 42(2), 244-257.
Sokka, T., & Pincus, T. (2009). Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol, 36(7), 1387-1390. doi:10.3899/jrheum.080770
Taylor, P., & Maini, R. (2017). Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis. In J. O'Dell (Ed.), UpToDate. Waltham. MA. Retrieved from https://www.uptodate.com/contents/investigational-biologic-markers-in-the-diagnosis-andassessment-of-rheumatoid-arthritis.
van der Heijde, D. M., van 't Hof, M. A., van Riel, P. L., Theunisse, L. A., Lubberts, E. W., van Leeuwen, M. A., van de Putte, L. B. (1990). Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis, 49(11), 916-920.
van der Helm-van Mil, A. H. M., Knevel, R., Cavet, G., Huizinga, T. W. J., & Haney, D. J. (2013). An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. In Rheumatology (Oxford) (Vol. 52, pp. 839-846).